Best practices for pediatric asthma: Improved clinical management for the inner-city patient

Journal of the National Medical Association

Volumn 91, Issue SUPPL., 1999, Pages

  Jones, Craig A ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b General Laboratories Bldg ^*  (United States)

Author keywords

Asthma; Barriers to care; Inner city

Indexed keywords

ANTIASTHMATIC AGENT;

ASTHMA; CHILD; CLASSIFICATION; DRUG MONITORING; ENVIRONMENTAL EXPOSURE; HEALTH SERVICE; HUMAN; HYPERSENSITIVITY; METHODOLOGY; PEAK EXPIRATORY FLOW; PRACTICE GUIDELINE; QUALITY CONTROL; REVIEW; RISK FACTOR; STANDARD; TREATMENT OUTCOME; UNITED STATES; VIRUS INFECTION;

ANTI-ASTHMATIC AGENTS; ASTHMA; BENCHMARKING; CHILD; DRUG MONITORING; ENVIRONMENTAL EXPOSURE; HUMANS; HYPERSENSITIVITY; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PEAK EXPIRATORY FLOW RATE; PRACTICE GUIDELINES; RISK FACTORS; UNITED STATES; URBAN HEALTH SERVICES; VIRUS DISEASES;

EID: 0033180788     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Crain EF, Kercsmar C, Weiss KB, Mitchell H, Lynn H. Reported difficulties in access to quality care for children with asthma in the inner city. Arch Pediatr Adolesc Med. 1998;152:333-339.
2. Halfon N, Newacheck PW. Childhood asthma and poverty: differential impacts and utilization of health services. Pediatrics. 1993;91: 56-61.
3. Billings J, Zeitel L, Lukomnik J, Carey TS, Blank AE, Newman L. Impact of socioeconomic status on hospital use in New York City. Health Aff Millwood. Spring 1993;12:162-173.
4. Evans D, Mellins R, Lobach K, Ramos-Bonoan C, Pinkett-Heller M, Wiesemann S, et al. Improving care for minority children with asthma: professional education in public health care clinics. Pediatrics. 1997;99:157-164.
5. US Department of Health and Human Services. Public Health Service. National Institutes of Health. National Heart, Lung, and Blood Institute. Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. NIH Publication No. 98-4051, July 1997.
6. Sarpong SB, Hamilton RG, Eggleston PA, Adkinson NF Jr. Socioeconomic status and race as risk factors for cockroach allergen exposure and sensitization in children with asthma. J Allergy Clin Immunol. 1996;97:1393-1401.
7. Rosenstreich DL, Eggleston P, Kattan M, Baker D, Slavin RG, Gergen P, et al. The role of cockroach allergy and exposure to cockroach allergen in causing morbidity among inner-city children with asthma. N Engl J Med. 1997; 336:1356-1363.
8. Arruda LK, Rizzo MC, Chapman MD, Fernandez-Caldas E, Baggio D, Platts-Mills TAE, et al. Exposure and sensitization to dust mite allergens among asthmatic children in São Paulo, Brazil. Clin Exp Allergy. 1991;21:433-439.
9. Pollart SM, Chapman MD, Fiocco GD, Rose G, Platts-Mills TA. Epidemiology of acute asthma: IgE antibodies to common inhalant allergens as a risk factor for emergency room visits. J Allergy Clin Immunol. 1989;83:875-882.
10. Sears MR, Herbison GP, Holdaway MD, Hewitt CJ, Flannery EM, Silva PA. The relative risks of sensitivity to grass pollen, house dust mite and cat dander in the development of childhood asthma. Clin Exp Allergy. 1989;19:419-424.
11. Koehler PG, Patterson RS, Brenner RJ. German cockroach (Orthoptera: Blattellidae) infestations in low-income apartments. J Econ Entomol. 1987;80:446-450.
12. Call RS, Smith TF, Morris E, Chapman MD, Platts-Mills TAE. Risk factors for asthma in inner city children. J Pediatr. 1992;121:862-866.
13. Glovsky MM, Miguel AG, Cass GR. Particulate air pollution: possible relevance in asthma. Allergy and Asthma Proc. 1997;18:163-166.
14. Kattan M, Mitchell H, Eggleston P, Gergen P, Crain E, Redline S, et al. Characteristics of inner-city children with asthma: the National Cooperative Inner-City Asthma Study. Pediatr Pulmonol. 1997;24:253-262.
15. Neas LM, Dockery DW, Ware JH, Spengler JD, Speizer FE, Ferris BG Jr. Association of indoor nitrogen dioxide with respiratory symptoms and pulmonary function in children. Am J Epidemiol. 1991;134:204-219.
16. Ostro BD, Lipsett MJ, Mann JK, Wiener MB, Seiner J. Indoor air pollution and asthma: results from a panel study. Am J Respir Crit Care Med. 1994;149:1400-1406.
17. Martinez FD. Definition of pediatric asthma and associated risk factors. Pediatr Pulmonol. 1997;15(suppl):9-12.
18. Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ, and the Group Health Medical Associates. Asthma and wheezing in the first six years of life. N Engl J Med. 1995;332:133-138.
19. Takahashi Y, Ohno H, Misawa M. Characteristics of vagal reflex-mediated tracheal response induced by bronchoconstriction in guinea pigs. Eur J Pharmacol. 1996;302:89-97.
20. Corcoran BM, Haigh AL. Effect of vagotomy and vagal cooling on bronchoconstrictor response to substance P in sheep. Respir Physiol. 1995;102:71-77.
21. Marney SR Jr. Pathophysiology of reactive airway disease and sinusitis. Ann Otol Rhinol Laryngol. 1996;105:98-100.
22. Busse WW, Calhoun WF, Sedgwick JD. Mechanism of airway inflammation in asthma. Am Rev Respir Dis. 1993;147:S20-S24.
23. Sears MR, Holdaway MD, Flannery EM, Herbison GP, Silva PA. Parental and neonatal risk factors for atopy, airway hyper-responsiveness, and asthma. Arch Dis Child. 1996;75: 392-398.
24. Laitinen LA, Laitinen A. Modulation of bronchial inflammation: corticosteroids and other therapeutic agents. Am J Respir Crit Care Med. 1994;150:S87-S90.
25. Greening AP, Ind PW, Northfield M, Shaw G, on behalf of Allen & Hanburys Limited UK Study Group. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet. 1994;344:219-224.
26. O'Connor BJ, Godard P, Dubé LM, Swanson LJ, Tountree LV, and the European Zileuton Study Group. The effect of a 5-lipoxygenase inhibitor, zileuton, plus low-dose inhaled beclomethasone compared to higher dose beclomethasone alone in patients with asthma. Am J Respir Crit Care Med. 1996;153:A803 [Abstract].
27. Nayak AS, Anderson PJ, Charous BL, Williams KL, Miller CJ, Bonuccelli CM, et al. Addition of zafirlukast compared with a double dosage of inhaled corticosteroids in asthmatic patients with symptoms on inhaled corticosteroids. Eur Respir J. 1998;12(suppl 28):361S [Abstract].
28. Leff JA, Israel E, Noonan MJ, Finn AF, Godard P, Lofdahl CG, et al. Montelukast (MK-0476) allows tapering of inhaled corticosteroids (ICS) in asthmatic patients while maintaining clinical stability. Am J Respir Crit Care Med. 1997;155:A976.
29. Zafirlukast for asthma. Med Lett Drugs Ther. 1996;38:111-112.